Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 4, 2007, Pages 840-843

  Castle, Philip E ^a   Sadorra, Mark ^b   Garcia, Francisco A R ^c   Cullen, Allison P ^d   Lorincz, Attila T ^d   Mitchell, Amy L ^c   Whitby, Denise ^e   Chuke, Ronald ^d   Kornegay, Janet R ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROCHE MOLECULAR SYSTEMS   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Digene Corporation   (United States)

^e SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER RISK; CANCER SCREENING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DNA DETERMINATION; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LABORATORY DIAGNOSIS; MOUTHWASH; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STORAGE; TRANSPORT MEDIUM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

CETYLPYRIDINIUM; CHI-SQUARE DISTRIBUTION; DNA, VIRAL; DRUG COMBINATIONS; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; QUATERNARY AMMONIUM COMPOUNDS; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS;

EID: 34247549723     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0909     Document Type: Article

References (17)

1. Kitchener HC, Castle PE, Cox JT. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006;24 Suppl 3:S63-70.
2. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
3. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-5.
4. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9.
5. Bosch FX, Manos MM, Munoz N, et al.; International biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
6. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
7. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
8. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64.
9. Wright TC, Jr., Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-90.
10. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004;122:238-45.
11. Carozzi FM, Del Mistro A, Confortini M, et al. Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting. Am J Clin Pathol 2005;124:716-21.
12. Garcia-Closas M, Egan KM, Abruzzo J, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001;10:687-96.
13. Carozzi F, Bisanzi S, Sani C, et al. Agreement between the AMPLICOR(R) HPV test and the Hybrid Capture(R) 2 assay in the detection of high-risk human papillomavirus and biopsy-confirmed high-grade cervical disease. J Clin Microbiol 2007;45:364-9.
14. Sandri MT, Lentati P, Benini E, et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol 2006;44:2141-6.
15. Castle PE, Garcia-Meijide M, Holladay EB, et al. A novel filtration-based processing method of liquid cytology specimens for human papillomavirus DNA testing by hybrid capture II. Am J Clin Pathol 2005;123:250-5.
16. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
17. Graviti PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 2003;12:477-84.